Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes

Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes (MDS). Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs1.

  • MDS, a group of rare and often underdiagnosed blood cancers, is characterized by a dysfunctional immune system and leukemic stem cell proliferation2-4.
  • Despite treatment with HMAs – the last treatment innovation in higher-risk (HR) MDS over …
/by

One billion antimalarial treatments delivered: An extraordinary partnership journey

Child receives dispersible antimalarial treatment in Kenya

Who would have thought that an ancient Chinese herbal remedy would one day become the panacea for malaria? Sweet wormwood (Artemisia annua) was indeed used in traditional Chinese medicine for more than 2 000 …

/by